Hostname: page-component-6bf8c574d5-t27h7 Total loading time: 0 Render date: 2025-02-17T15:52:22.973Z Has data issue: false hasContentIssue false
  • English
  • Français

Successful use of ivabradine in a 10-year-old patient with graft failure after heart transplantation

Published online by Cambridge University Press:  22 July 2022

Yosuke Ogawa Open the ORCID record for Yosuke Ogawa [Opens in a new window] ,
Susumu Urata  and
Ryo Inuzuka Open the ORCID record for Ryo Inuzuka [Opens in a new window]
Yosuke Ogawa
Affiliation:
Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan
Susumu Urata
Affiliation:
Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan
Ryo Inuzuka*
Affiliation:
Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan
*
Author for correspondence: R. Inuzuka, MD, PhD, Department of Pediatrics, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. Tel: +81-3-3815-5411. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

We encountered a paediatric case of graft failure due to antibody-mediated rejection after heart transplantation in which ivabradine was effective. Inappropriate sinus tachycardia in denervated transplanted hearts is a good indication for ivabradine administration as beta-blockers have a limited efficacy. To our knowledge, this is the first report on the effectiveness of ivabradine in a paediatric heart transplant rejection case.

Keywords

Ivabradinepaediatricsheart failureheart transplantationinappropriate sinus tachycardiadenervated hearts
Type
Brief Report
Information
Cardiology in the Young , Volume 33 , Issue 4 , April 2023 , pp. 649 - 651
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Colvin, MM, Cook, JL, Chang, P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation 2015; 131: 1608–1639.CrossRefGoogle ScholarPubMed
Koruth, JS, Lala, A, Pinney, S, Reddy, VY, Dukkipati, SR. The clinical use of ivabradine. J Am Coll Cardiol 2017; 70: 1777–1784.CrossRefGoogle ScholarPubMed
Borer, JS, Böhm, M, Ford, I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J 2012; 33: 2813–2820.CrossRefGoogle ScholarPubMed
Bonnet, D, Berger, F, Jokinen, E, Kantor, PF, Daubeney, PEF. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol 2017; 70: 1262–1272.CrossRefGoogle ScholarPubMed
Rivinius, R, Helmschrott, M, Rahm, AK, et al. Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation. Clin Res Cardiol 2022; 111: 141–153.CrossRefGoogle ScholarPubMed
Fang, Y, Debunne, M, Vercauteren, M, et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Phamacol 2012; 59: 260–267.CrossRefGoogle ScholarPubMed
Izumida, T, Imamura, T, Nakamura, M, Fukuda, N, Kinugawa, K. How to consider target heart rate in patients with systolic heart failure. ESC Heart Fail 2020; 7: 3231–3234.CrossRefGoogle ScholarPubMed